Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ARNA 6.18 -0.12 (-1.90%)
price chart
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): TV Ads For Belviq Launched
Dallas, Texas 04/17/2014 (ustradevoice) - One of the main reasons, analysts and pundits say, why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has not had success with its FDA-approved weight management drug known as Belviq, is lack of awareness.
Arena Pharmaceuticals Sees Large Decrease in Short Interest (ARNA)  Mideast Time
Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology ...  Tech News
Related articles »  
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The Future Is Encouraging
That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have come to the realization that unless it takes proactive steps to expand the market share of its anti-obesity drug Belviq, it might as well miss out on a great opportunity.
Biotech Movers: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals ...
Biotech Movers: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD). Posted by Stephanie Byars on Apr 18, 2014. On April 17, 2014, Health ...
Related articles »  
What Arena's Belviq Television Ad Campaign Means For The Stock
The weight loss drug Belviq from Arena Pharmaceuticals (ARNA) is now being promoted on television with a national advertising campaign.
Investor's Watch List -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Incyte ...
Las Vegas, NV - April 18, 2014 - (TechSonian) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and fiscal year which ended on December 31, 2013.
Related articles »  
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Expecting Sales to hit $150M this ...
Dallas, Texas 03/31/2014 (ustradevoice) - Biopharmaceutical Company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), expects majority of its revenue for the year to come from its flagship drug, Belviq.
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL ...
Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at: On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a ...
Related articles »  
Arena Pharmaceuticals, Inc. (ARNA) news: Direct-To-Consumer Television ...
Arena (ARNA) and its marketing partner Eisai (OTCPK:ESALY) recently announced a major new stage in commercialization strategy and promotional mix that I believe could be the tipping point for a significant upward inflection in BELVIQ sales.
Stocks Alert: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Arena ...
Inovio Pharmaceuticals Inc(NYSEMKT:INO)'s shares is trading at $2.60. The company on Apr. 1 announced the appointment of E.J.
Arena - Belviq Sales Up Modestly Heading Into Television Ads
It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way.
Related articles »